Physician profile
Edward Burke
NPI 1306885157
$3,418.28
in general payments reported to CMS, 2019-2025
40 companies · $898 in 2025
The $898 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $256 · 2021: $615 · 2022: $499 · 2023: $397 · 2024: $418 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.80 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $544.52 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Allergan, INC. | $277.02 | 2019-2020 | |
| Lundbeck LLC | $222.75 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $206.84 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $192.82 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $181.43 | 2022-2025 | Austedo, Austedo Xr |
| Mimedx Group, INC. | $180.78 | 2024-2025 | |
| Glaxosmithkline, LLC. | $159.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $129.62 | 2019-2025 | Rybelsus, Ozempic |
| Vanda Pharmaceuticals INC. | $110.76 | 2021-2022 | |
| Amarin Pharma, INC. | $102.85 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $97.42 | 2019-2021 | |
| Lilly USA, LLC | $90.24 | 2021-2025 | Mounjaro, Baqsimi |
| Avanir Pharmaceuticals, INC. | $85.11 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.41 | 2022-2025 | Caplyta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.